scholarly journals Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro

2022 ◽  
Vol 15 (1) ◽  
pp. 101243
Author(s):  
Gamze Guney Eskiler ◽  
Asuman Deveci Ozkan ◽  
Ayten Haciefendi ◽  
Cemil Bilir
2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Susanne Hafner ◽  
Menna El Gaafary ◽  
Christoph Q Schmidt ◽  
Tatiana Syrovets ◽  
Thomas Simmet

Life Sciences ◽  
2014 ◽  
Vol 119 (1-2) ◽  
pp. 47-55 ◽  
Author(s):  
Jisun Lee ◽  
Seul Lee ◽  
Sun-Lim Kim ◽  
Ji Won Choi ◽  
Jeong Yeon Seo ◽  
...  

2010 ◽  
Vol 5 (1) ◽  
pp. 108 ◽  
Author(s):  
Justine Rudner ◽  
Carola-Ellen Ruiner ◽  
René Handrick ◽  
Hans-Jörg Eibl ◽  
Claus Belka ◽  
...  

Marine Drugs ◽  
2019 ◽  
Vol 17 (10) ◽  
pp. 585 ◽  
Author(s):  
Adrien Bosseboeuf ◽  
Amandine Baron ◽  
Elise Duval ◽  
Aude Gautier ◽  
Pascal Sourdaine ◽  
...  

The purpose of the present paper is to investigate the mechanism of action of a pyroglutamate-modified peptide (pE-K092D) on in vitro growth inhibition of MDA-Pca-2b prostate cancer cells. This peptide was derived from a peptide previously isolated from the testis of the lesser spotted dogfish and identified as QLTPEALADEEEMNALAAR (K092D). The effect of the peptide on cell proliferation and cell death mechanisms was studied by flow cytometry. Cellular morphology and cytoskeleton integrity of peptide-treated cells were observed by immunofluorescence microscopy. Results showed the onset of peptide induced early cytoskeleton perturbation, inhibition of autophagy, inhibition of cell proliferation and, at the end, non-apoptotic cell death mechanisms (membrane destabilization and necrosis). All those mechanisms seem to contribute to MDA-Pca-2b growth inhibition by a main cytostatic fate.


The Prostate ◽  
2013 ◽  
Vol 73 (12) ◽  
pp. 1306-1315 ◽  
Author(s):  
Simeng Wen ◽  
Zhiqun Shang ◽  
Shimiao Zhu ◽  
Chawnshang Chang ◽  
Yuanjie Niu

Sign in / Sign up

Export Citation Format

Share Document